Inactive Instrument

Highlights Kazia Therapeutics Australian S.E.

Equities

Kazia Therapeutics Limited Reports Successful Stage 1 Completion of the EVT801 Phase 1 Clinical Trial in Advanced Cancer Patients	May. 01	CI
Kazia Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31, 2023	Mar. 27	CI
Kazia Therapeutics Limited Enters into an Exclusive Licensing Agreement Withsovargen Co., Ltd	Mar. 21	CI
Kazia Therapeutics' Lead Drug Candidate Meets Goal of Early-Stage Study	Feb. 21	MT
Kazia Therapeutics Limited Reports Early Conclusion of Clinical Trial After Reaching Primary Endpoint	Feb. 21	CI
Kazia Announces Non-Binding Letter of Intent for the Proposed Granting of Rights to Develop and Commercialize Paxalisib Outside of Oncology	Nov. 29	CI
Kazia Therapeutics Signs Letter of Intent for Rights Licensing Deal	Nov. 29	MT
Kazia Therapeutics Limited Reports Earnings Results for the Full Year Ended June 30, 2023	23-08-31	CI

No results for this search